✓ Revise Right course
Monoclonal antibodies bind to specific antigens on cancer cells and deliver attached drugs directly to them. Free notes and 13 questions answered.
Therapeutic Uses and Limitations of Monoclonal Antibodies is part of Monoclonal antibodies (biology only) (HT only) in GCSE AQA Higher Biology.
4 min
Reading time
17
Lessons in this topic
GCSE AQA Higher
Pathway
Reviewed by Revise Right
Content review
Monoclonal antibodies bind to specific antigens on cancer cells and deliver attached drugs directly to them. Free notes and 13 questions answered.
AQA GCSE Biology mock draft, 26–31 Oct. Draft coverage: Biology Paper 1 (Higher tier). Reviewed for an original-practice sitting; check student availability before registering. Marking and results will follow later, after separate approval. Eligible new accounts receive a five-day Pro trial when signup email verification completes. Previous trials keep their original expiry. After expiry, new papers need Pro unless you have an explicitly confirmed free sitting offer for this event. That offer adds no Pro time or AI learning. Saved attempts and released results remain readable. No card or automatic charge.
Use this lesson to stay inside Monoclonal antibodies (biology only) (HT only) while connecting the detail back to the wider Infection and response topic.
Read the core explanations from Therapeutic Uses and Limitations of Monoclonal Antibodies before testing yourself from memory.
When monoclonal antibodies were first developed, scientists thought they'd revolutionise medicine. The idea was brilliant: create identical antibodies that could hunt down specific targets in the body like guided missiles. Cancer cells would be destroyed while healthy cells remained untouched.
The reality has been more complex. While monoclonal antibodies do work for some diseases, they've created more side effects than expected and aren't as widely used as everyone hoped. Let's explore why.
Think of monoclonal antibodies as molecular postmen with a very specific address. They can only deliver their 'package' to cells displaying the right 'postcode' - the specific antigen they recognise.
The clever part is what they deliver. Scientists can attach different substances to these antibodies:
Radioactive substances: These emit radiation that kills cancer cells from the inside. The antibody ensures the radiation only affects cancer cells, not healthy tissue nearby.
Toxic drugs: Powerful cell-killing chemicals that would be too dangerous to give normally. The antibody acts like a protective escort, delivering the poison directly to cancer cells.
Growth-stopping chemicals: Substances that prevent cells from dividing. Cancer cells rely on rapid division to spread, so stopping this process can halt the disease.
Monoclonal antibodies are used to treat several conditions, though not as widely as originally hoped. Here are the main applications:
Cancer treatment: Some breast cancers produce too much of a protein called HER2. Monoclonal antibodies can bind to HER2 and either block its function or deliver toxic drugs directly to these cancer cells.
Autoimmune diseases: In conditions like rheumatoid arthritis, the immune system attacks healthy joints. Monoclonal antibodies can block specific immune signals that cause this damage.
Transplant rejection: After organ transplants, monoclonal antibodies can suppress specific immune responses that would reject the new organ, while leaving other immune functions intact.
Worked example: How Cancer Treatment with Monoclonal Antibodies Works
Explain how a monoclonal antibody delivers a toxic drug to a breast cancer cell expressing HER2 protein.
Answer: The monoclonal antibody acts as a guided delivery system, ensuring toxic drugs reach only cancer cells expressing the target antigen.
Despite their promise, monoclonal antibodies have significant limitations that have prevented them from becoming the miracle cure scientists hoped for.
Unexpected side effects: Even though monoclonal antibodies are designed to be specific, they often cause more side effects than predicted. This happens because:
• The target antigen might be found on some healthy cells too, not just diseased ones• The immune system can react against the monoclonal antibodies themselves• The attached drugs or radioactive substances can still cause damage to nearby healthy tissue
High cost and complexity: Producing monoclonal antibodies requires sophisticated laboratory facilities and is extremely expensive. This limits their availability and makes treatment costly.
Limited effectiveness: Many cancers don't have suitable target antigens, or they develop resistance by stopping production of the target protein.
Exam questions often give you information about a specific monoclonal antibody treatment and ask you to explain how it works. Here's your strategy:
Exam depth extension: In therapeutic uses and limitations of monoclonal antibodies, connect the promise and reality of monoclonal antibodies to how monoclonal antibodies work as medicine using clear cause-and-effect statements. When you explain biological processes, include what changes, why it changes, and the consequence for cells, organisms, or populations. If calculations appear, show each step, include units, and end with a sentence that interprets the result in biological context.
Command word focus: When asked to 'describe' how a treatment works, focus on what happens step by step. When asked to 'explain', include why each step happens and what the advantages are.
Common mistake: Don't say monoclonal antibodies 'boost the immune system' - they work by targeting specific antigens, not by general immune enhancement.
Published by Revise Right. Use the official specification reference to check the requirements for your course. Content updated: 2026-03-20.
Move to the related lessons or back to the topic page when you need the wider sequence before exam-style practice.
Monoclonal antibodies are not as widely used as hoped because they have created more side effects than expected, producing them requires sophisticated laboratory facilities and is extremely expensive, and many cancers do not have suitable target antigens or stop producing the target protein.
Monoclonal antibodies cause more side effects than expected, because the target antigen may be found on some healthy cells, the immune system can react against the antibodies, and attached drugs can damage nearby healthy tissue. They are also extremely expensive to produce, and many cancers lack suitable target antigens or develop resistance.
Monoclonal antibodies treat cancer by binding to specific antigens on cancer cells and delivering attached substances directly to them: radioactive substances, toxic drugs or chemicals that stop cells dividing. For example, antibodies that bind to HER2 protein on some breast cancer cells deliver a toxic drug while leaving healthy cells unharmed.
Radioactive substances, toxic drugs and growth-stopping chemicals can be attached to monoclonal antibodies. The antibody delivers its package only to cells displaying the specific antigen it recognises, so radiation or cell-killing chemicals affect the target cells and not healthy tissue.
Monoclonal antibodies are used to treat some cancers, such as breast cancers that produce too much HER2 protein, autoimmune diseases like rheumatoid arthritis by blocking specific immune signals, and transplant rejection by suppressing specific immune responses while leaving other immune functions intact.
Some breast cancers produce too much of a protein called HER2, and monoclonal antibodies can bind to HER2 to block its function or deliver toxic drugs directly to these cancer cells. Healthy cells do not have HER2, so they do not receive the toxic drug.
Monoclonal antibodies cause more side effects than predicted because the target antigen may also be found on some healthy cells, the immune system can react against the antibodies themselves, and attached drugs or radioactive substances can still damage nearby healthy tissue.
After organ transplants, monoclonal antibodies can suppress specific immune responses that would reject the new organ, while leaving other immune functions intact. They work by targeting specific antigens rather than suppressing the whole immune system.
In autoimmune diseases such as rheumatoid arthritis, where the immune system attacks healthy joints, monoclonal antibodies can block specific immune signals that cause this damage.
Monoclonal antibodies do not boost the immune system in general; they work by targeting specific antigens. Saying they 'boost the immune system' is a common mistake.
Monoclonal antibody treatments are expensive because producing them requires sophisticated laboratory facilities and is extremely costly. This limits their availability and makes treatment costly, one reason they are not as widely used as first hoped.
Monoclonal antibodies do not work for every cancer because many cancers do not have suitable target antigens, or they develop resistance by stopping production of the target protein. The antibodies can only deliver treatment to cells displaying the antigen they recognise.
Radioactive substances attached to monoclonal antibodies emit radiation that kills cancer cells from the inside. The antibody binds only to cells with its target antigen, so the radiation mainly affects cancer cells rather than healthy tissue nearby.